Who We Are
Leading the future of healthcare through innovation, research, and unwavering commitment to global well-being since 1993.
Group Companies
Four Decades of Growth Driven by Purpose Founded in 1983, Synokem Pharmaceuticals began as a modest formulation unit with a singular mission: to make quality healthcare accessible and affordable to all. Today, Synokem is a globally recognized pharmaceutical company, trusted in over 30 countries.
Over the years, Synokem group has made significant investments in additional greenfield projects (Synokem Lifesciences Private Limited), key acquisitions in Injectables CDMO space (Nitin Lifesciences Limited)and forayed into new lines of businesses like Branded Generics products (Kemsyn Lifesciences Private Limited) in order to consolidate itself as an End to End Integrated Pharmaceutical player to cater patient’s needs across products, dosage forms and different trade channels. This has enabled Synokem get a strong foothold in the larger Pharma ecosystem and prepared it for the next phase of growth to become the industry leader.
SYNOKEM LIFESCIENCES PRIVATE LIMITED (Wholly owned subsidiary of Synokem Pharmaceutical Limited)
Synokem Lifesciences Private Limited was incorporated in 2022 with state-of-the-art manufacturing, quality and R&D capabilities. Also known as Plant 3, Synokem Lifesciences offers dosage forms such as Tablets, capsules and a recently commissioned Liquid line. The plant is aggressively ramping up on strong order book driven by our Manufacturing strength, Product Quality, Technological capabilities and the trust & confidence put by our esteemed customers.
NITIN LIFESCIENCES LIMITED (Wholly owned subsidiary of Synokem Pharmaceutical Limited)
For over three decades, Nitin Lifesciences Ltd. has been a cornerstone of India's pharmaceutical manufacturing landscape. Established in 1994 with a facility in Karnal, Haryana, Nitin Lifesciences has grown into one of the country's largest manufacturers of Small Volume Parenteral (SVPs). Our journey is marked by a relentless commitment to quality, innovation, and strategic growth, culminating in our new chapter as a proud member of the Synokem Group. As a leading Contract Development and Manufacturing Organization (CDMO), we are the trusted partner for major Indian pharmaceutical companies and multinational corporations, delivering excellence in every vial and ampoule, produced by us.
Our Journey: A Legacy Of Growth
Why Choose Nitin Lifesciences?
Strategic Group Advantage
As part of the leading Indian CDMO, the Synokem Group, we offer enhanced capabilities and resources. We leverage the support of Synokem’s advanced R&D facility to develop and introduce new injectable products.
Financial Stability
We are a zero-debt company, empowering us to readily invest in future projects and create bespoke infrastructure to meet our clients & unique requirements.
Unmatched Expertise
With over 30 years of specialized experience in aseptic parenteral processing, we possess deep knowledge in handling complex injectable manufacturing.
Global Quality Standards
Our facilities are WHO-GMP Certified and accredited by the FDA of various other countries, ensuring our products meet stringent international quality benchmarks.
Large-Scale Production
We have extensive capacities to produce bulk quantities efficiently, making us a reliable partner for large-scale contract manufacturing projects.
Dedicated Professional Team
The strength of our organization lies in our highly committed, experienced, and dedicated team of approximately 500 professionals across our three manufacturing facilities.
A New Era Of Modernization And Expansion
Following the acquisition by Synokem, we have initiated a comprehensive upgradation strategy backed by a massive capital expenditure plan of ₹50.00 Cr. This investment is dedicated to elevating all three of our manufacturing facilities to be at par with EU GMP Guidelines.
Key Modernization Milestones
Cepha Block Revamp
The Cephalosporin block at our Paonta Sahib facility has been completely revamped and upgraded, commencing commercial production on August 27, 2025.
New Quality Control Lab
A new Quality Control and Microbiology Lab, equipped with the latest testing equipment, has been commissioned in Q4'2025.
Advanced Water System
A new, modern SWFI & PW System is under erection and will be commissioned by November 30, 2025.
State-Of-The-Art Manufacturing Facilities
Headquartered in Delhi, Nitin Lifesciences operates three WHO-GMP certified manufacturing facilities. Headquartered in Delhi, Nitin Lifesciences operates three WHO-GMP certified manufacturing facilities.
1. Karnal, Haryana
- Established: 1994.
- Infrastructure: Built on 2,760 sq. mts. of land with a covered area of over 50,000 sq. ft.
- Specialization: Recently upgraded as per Revised Schedule M guidelines, this facility has a dedicated Dry Powder Injection (DPI) line for Beta Lactam products.
- Annual Capacity: 6–7 million vials.
2. Paonta Sahib (P1), Himachal Pradesh
- Established: 2005–06.
- Infrastructure: Spread over 9,000 sq. mts. with a covered area of approximately 1.00 lac sq. ft.
- Facility Blocks:
- • Cephalosporin Block: Recently revamped with a new Dry Powder Filling & Sealing Line. Annual Capacity: Approximately 50 million dry powder vials.
- • General Block: Equipped with 2 Liquid Vial Lines, 3 Liquid Ampoule Lines, and 1 Eye/Ear Drop Line. Scheduled for a complete upgrade to become a state-of-the-art facility by mid-2026.
- Annual Capacity: Approximately 200 million total filled units.
3. Paonta Sahib (P3), Himachal Pradesh
- Established: 2014.
- Infrastructure: A state-of-the-art facility spread over 20,000 sq. mts. with more than 1.50 lacs sq. ft. of covered area.
- Capabilities: Equipped with 2 Liquid Vial Lines, 2 Liquid Ampoule Lines, and 1 DPI Line for General (Non-Beta Lactam) products. It also features 2 Lyophilisers for manufacturing Lyo products.
- Annual Capacity: 200 million units across liquid, lyophilized, and dry powder products.
Our Product Portfolio & Capabilities
We specialize in manufacturing over 200 formulations across a wide spectrum of therapeutic areas, including:
- Antibiotics
- Anti-malarial
- NSAIDs
- Anti-inflammatory drugs
- Local anesthetics
- Nutritional products
Digital Transformation & Future Prospects
In line with the vision of our parent company, Synokem, we are committed to digital excellence. We successfully implemented SAP HANA 4 in June 2025 to digitize our operations and are continuously exploring new digital tools to enhance efficiency.
Looking ahead, Nitin is actively exploring new drug delivery systems, with a project to install a Pre-filled Syringe (PFS) & Cartridge with Pen Filling Line, for GLP-1, Peptides and Insulin Analog, which is in a very advanced stage of finalization. We are also in the process of developing new molecules for both domestic and export markets, building on our reputation as a quality-conscious exporter to more than 11 countries.
KEMSYN LIFESCIENCES PRIVATE LIMITED (Wholly owned subsidiary of Synokem Pharmaceutical Limited)
At Kemsyn Lifesciences Private Limited, we are more than just a pharmaceutical company – we are your trusted partner in health. As part of the renowned Synokem Pharmaceuticals group, we combine decades of experience, state-of-the-art facilities, and cutting-edge innovation to meet global healthcare needs.
With three WHO-GMP-certified units, access to advanced research through Nitin Lifesciences, and a portfolio of 300+ high-quality SKUs, we are dedicated to improving patient lives with reliable, effective, and affordable solutions.